Page 2 - V1 2016 Product Catalog

NewProducts Available from ASD Healthcare
ASD Healthcare is now an authorized distributor for several new products, which are described below. We continuously expand our product lines to make sure you have access to the products you need, when you need them. To verify a product is appropriate for your facility to order, simply call your sales representative. We’re always here to help you.
FLUADTM
Manufactured by Seqirus, FLUAD (influenza vaccine, adjuvant) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine in persons 65 years of age and older. For specific product information, please see page 16 in our Product Catalog.
Imatinib
Manufactured by Ranbaxy, Imatinib is the ge- neric form of Gleevec (Novartis) and is indicated for the treatment of patients with certain types of leukemia or gastrointestinal stromal tumors. For specific product information, please see page 13 in our Product Catalog.
KanumaTM
Manufactured by Alexion Pharmaceuticals, Kanuma received FDA approval as the first treatment for patients with lysosomal acid lipase (LAL) deficiency. LAL deficiency is a rare inherited enzyme disorder that can lead to serious and life-threatening organ damage, especially when onset begins in infancy. FDA also granted Kanuma orphan drug status.
For specific product information, please see page 18 in our Product Catalog.
MYOBLOC®
Manufactured by Solstice Neurosciences, LLC, MYOBLOC (rimabotulinumtoxinB) Injection is indicated for the treatment of adults with cervi- cal dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
For specific product information, please see page 19 in our Product Catalog.
ONCASPAR®
Manufactured by Baxalta, Inc., ONCASPAR (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL) and for the treat- ment of patients with ALL and hypersensitivity to native forms of L-asparaginase.
For specific product information, please see page 13 in our Product Catalog.
OTIPRIOTM
Manufactured by Otonomy, Inc., OTIPRIO (a single-dose ciprofloxacin otic suspensension) is indicated for the treatment of bilateral otitis media with effusion in pediatric patients who are undergoing tympanostomy tube placement. For specific product information, please see page 19 in our Product Catalog.
For quick and updated product information on our most popular products, including these new products, please see our Product Catalog on page 3.
2 | InsideOut